Mobile

A 26 week randomised, parallel three-arm, open-label, multi-centre, multinational treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide versus insulin degludec or...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-021560-15

A 26 week randomised, parallel three-arm, open-label, multi-centre, multinational treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide versus insulin degludec or liraglutide alone, in subjects with type 2 iabetes treated with 1-2 oral anti-diabetic drugs (OADs)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in subjects with type 2 diabetes. This is done by comparing the difference in change in HbA1c from baseline after 26 weeks of treatment to a non-inferiority limit of 0.3% for insulin degludec/liraglutide vs insulin degludec and to a superiority limit of 0% for insulin degludec/liraglutide vs liraglutide.

Critère d'inclusion

  • Type 2 Diabetes

Liens